WIN Consortium—challenges and advances-Reference-Cited by-同舟云学术

WIN Consortium—challenges and advances

Published:2011-03 Issue:3 Volume:8 Page:133-134
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Mendelsohn John,Tursz Thomas,Schilsky Richard L.,Lazar Vladimir

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.nature.com/articles/nrclinonc.2010.230.pdf

Reference3 articles.

1. Kim, E. S. et al. The BATTLE Trial (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing therapy for lung cancer. Proceedings of American Association of Cancer Research (Late Breaking Abstracts-1) (2010).

2. Wistuba, I. I. et al. Methodological and practical challenges for personalized cancer therapies. Nat. Rev. Clin. Oncol. 8, 135–141 (2011).

3. Bang, Y. et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (18 Suppl.), a3 (2010).

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology;Therapeutic Advances in Medical Oncology;2023-01

2. Improving the Capacity to Treat Depression using Talking Therapies;The Wiley Handbook of Positive Clinical Psychology;2016-04-22

3. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma;Pathology & Oncology Research;2015-08-14

4. Overview of challenges and opportunities in drug delivery and pharmaceutics;Therapeutic Delivery;2015-08

5. Machine learning for biomarker identification in cancer research – developments toward its clinical application;Personalized Medicine;2015-08